Name: 글로벌 시장 동향
SKU: PH7181
Availability: InStock

보고서 요약(국문)

개요
전 세계 간성 뇌증 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 간성 뇌증 치료 시장은 수년간 상당한 성장과 변화를 보여왔으며, 다양한 요인들이 시장 역학에 영향을 미치고 있습니다. 간부전 및/또는 문맥-전신 단락으로 인해 정상적인 뇌 기능이 손상되는 증상을 간성 뇌증이라고 합니다. 간경변 환자의 약 40%가 치료 중 간성 뇌증을 경험합니다. 또한, 간성 뇌증의 첫 발병은 약 40%에서 재발을 예고합니다.
특히 개발도상국을 중심으로 한 정부 투자 및 연구는 완하제나 항생제와 같은 신약의 활용을 촉진하고 전 세계 간성 뇌증 치료 시장의 성장을 견인할 것입니다. 각각의 혁신적인 치료법은 여러 연구자들이 개발 중이며 현재 임상 시험 단계에 있습니다.
시장 동향: 성장 동인 및 제약 요인
자금 조달 및 인수 합병 증가
선진국들은 높은 투자, 소득 수준 및 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서는 연구 활동 증가로 인해 간성 뇌증 치료에 대한 수요가 크게 증가했습니다. 다양한 국가 간의 협력, 인수 합병 및 기술 발전에 따른 신제품 출시는 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2023년 3월 28일, 유메크린 코그니션(Umecrine Cognition)은 3,160만 스웨덴 크로나(SEK)의 신규 자금 조달에 성공하여 신약 개발 사업을 더욱 진전시켰습니다. 유메크린 코그니션은 인지 장애 치료를 위해 새로운 계열의 의약품을 개발하고 있습니다. 현재 간성 뇌병증(HE; 간성 혼수) 및 원발성 담즙성 담관염(PBC) 환자 치료를 위해 개발 중인 골렉사놀론은 이 회사의 가장 앞선 신약 후보 물질입니다.
이러한 심각한 질환은 뇌 기능에 영향을 미쳐 극심한 피로감, 집중력 저하, 운동 협조 능력 저하와 같은 증상을 유발합니다. 이전 임상 및 전임상 연구 결과는 골렉사놀론이 이러한 뇌 기능 장애를 보완할 수 있다는 가설을 강력하게 뒷받침합니다.
또한, 다양한 개발 목적을 위한 높은 수준의 연구와 신기술 활용이 증가하고 있습니다. 간성 뇌병증 환자 수의 증가와 혁신적인 치료법 개발을 위한 연구 증가는 간성 뇌병증 치료 시장 성장을 견인하는 주요 요인이 될 것입니다.
간성 뇌병증 약물과 관련된 부작용
리팍시민은 전신적으로 흡수되지 않으므로 내약성이 우수합니다. 대조 시험에서 이상 반응으로 인한 탈락률은 리팍시민과 위약 모두 0.4%였습니다. 식욕 부진, 설사, 미각 상실, 코막힘은 드문 부작용입니다. 리팍시민 투여 환자는 메스꺼움, 위장 장애, 피로, 어지럼증, 말초 부종, 근육 경련과 같은 약물 부작용을 경험할 수 있습니다.
장기간 사용은 세균 또는 진균 중복 감염과도 관련이 있습니다. 광범위하게 사용되고 있음에도 불구하고, 리팍시민이 혈청 효소 수치를 증가시키거나 임상적으로 명백한 간 손상을 유발한다는 증거는 미미합니다.
세분화 분석
전 세계 간성 뇌증 치료제 시장은 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
항생제 부문은 시장 점유율의 약 39%를 차지했습니다.
리팍시민은 흡수되지 않는 경구용 항생제입니다. 리팍시민은 비침습성 대장균 균주로 인한 여행자 설사 치료 외에도 성인의 간성 뇌증 치료 및 과민성 대장 증후군 관련 설사 관리에도 사용됩니다. 리팍시민은 광범위한 혐기성 및 호기성 그람 양성 및 그람 음성 세균에 효과적입니다.
흡수되지 않는 특성 때문에 이 항생제는 주로 위장관 감염 치료에 사용됩니다. 리팍시민은 흡수되지 않으므로 위장관 내강에 고농도로 축적되어 전신 부작용 없이 다양한 위장관 질환을 치료할 수 있습니다. 장외 미생물에서 리팍시민에 대한 세균 변형이나 내성은 매우 드뭅니다.

ASKA Pharmaceutical Holdings Co., Ltd.의 완전 자회사인 ASKA Pharmaceutical Co., Ltd.는 2023년 6월 22일, 간성 뇌증으로 인한 고암모니아혈증 치료를 위해 소아 환자에게 RIFXIMA TABLETS(리팍시민)의 생산 및 유통 허가 일부를 변경하는 신청서를 제출했습니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 35%를 차지했습니다.
간성 뇌증 치료에 대한 의료 수요가 증가함에 따라 북미 지역 제조업체들은 사업 확장의 기회를 갖고 있습니다. 북미에는 많은 생산업체와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 간성 뇌증 치료에 대한 수요를 견인하고 있습니다.

의료비 지출 증가, 연구 투자 확대, 기술 및 다양한 의약품 개발, 그리고 이 지역 전반에 걸친 바이오제약 또는 생명공학 기업 설립 증가는 이 지역의 간성 뇌증 치료 시장 점유율 성장에 기여하고 있습니다. 다양한 신약 승인 제품에 대한 인식이 높아짐에 따라 이 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 차지하는 지배적인 위치를 더욱 뒷받침합니다.
북미는 미국을 중심으로 전 세계 간성 뇌증 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 첨단 기술 발전에 대한 집중적인 투자는 미국 내 간성 뇌증 치료 수요를 촉진했습니다. 미국은 간성 뇌증 치료 수요를 자극하는 여러 정책 및 연구를 적극적으로 추진해 왔습니다.

COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 전 세계 간성 뇌증 치료제 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄, 공급망 차질, 경제 활동 위축에 직면하면서 다양한 의약품을 주요 소비처로 하는 제약 부문은 심각한 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치는 전 세계적으로 여러 사업에 영향을 미쳤습니다.
주요 의료 및 제약 산업은 활동을 중단하고 COVID-19 관리에 집중하면서 간성 뇌증 치료제 수요가 급감했습니다. 그러나 현재 여러 연구가 재개되었고 기업들은 제품 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로 팬데믹이 전 세계 간성 뇌증 치료제 시장에 미치는 영향은 비교적 완만할 것으로 예상되며, 혁신적인 치료법에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.

주요 개발 사항
• 2023년 6월 19일, 바우쉬 헬스 컴퍼니(Bausch Health Companies Inc.)와 그 소화기 사업부인 살릭스 파마슈티컬스(Salix Pharmaceuticals)가 제공한 XIFAXAN(리팍시민) 데이터가 2023년 유럽 간학회(EASL) 학술대회의 간경변 및 그 후유증 세션에 포함될 자료로 선정되었습니다.
• 2021년 6월 30일, 액셀라(Axcella)의 지속성 현성 간성 뇌증(OHE) 위험 감소를 위한 다중 표적 경구용 치료제 후보물질인 AXA1665가 초기 임상 시험 기관에 진입하여 전 세계 2상 임상 시험을 위한 환자 선별을 시작했습니다. 액셀라는 내인성 대사 조절제(EMM) 조성물을 활용하여 복잡한 질병을 치료하고 건강을 증진하는 새로운 접근법을 개발한 임상 단계의 생명공학 회사입니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Axcella Therapeutics, COSMO PHARMACEUTICALS, Umecrine Cognition AB, Salix Pharmaceuticals (Bausch Health Companies Inc.), ASKA Pharmaceutical Holdings Co., Ltd., Lupin, Norgine, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Austria GmbH 및 Fengchen Group Co.,Ltd. 등이 있습니다.
보고서 구매 이유

• 약물, 투여 경로, 유통 채널 및 지역별 글로벌 간성 뇌증 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 간성 뇌증 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

전 세계 간성 뇌증 치료 시장 보고서는 약 61개의 표, 59개의 그림, 그리고 186페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global overt hepatic encephalopathy treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global overt hepatic encephalopathy treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The symptomatic impairment of normal brain function brought on by hepatic failure and/or portosystemic shunting is known as overt hepatic encephalopathy. About 40% of cirrhotic patients experience it during their therapeutic treatment. In 40% of individuals, a first incidence of overt encephalopathy signals recurrence.
Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like laxatives or antibiotics and boost the global overt hepatic encephalopathy treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.
Market Dynamics: Drivers & Restraints
Growing funding and acquisitions
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for overt hepatic encephalopathy treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.
On March 28, 2023, the company's medication development initiatives are moving forward thanks to fresh finance of SEK 31,6 million obtained by Umecrine Cognition. To treat cognitive disorders, Umecrine Cognition is creating a new class of medicines. Currently being developed for the treatment of individuals with hepatic encephalopathy (HE; liver coma) and primary biliary cholangitis (PBC), golexanolone is the company's most advanced medication candidate.
Due to the severe diseases' impact on brain function, symptoms such intense weariness, trouble concentrating, and poor motor coordination develop. Previous clinical or pre-clinical study findings overwhelmingly support the idea that golexanolone can compensate for such impaired brain function.
Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising overt hepatic encephalopathy cases and increasing research for innovative treatment development will be a major factor driving the growth of the overt hepatic encephalopathy treatment market.
Side effects associated with the overt hepatic encephalopathy medications
Because rifaximin is not absorbed systemically, it is well tolerated. The dropout rates for adverse events in controlled trials were 0.4% for both rifaximin and the placebo. Anorexia, diarrhea, taste loss, and nasal passage discomfort are rare side effects. Rifaximin patients may experience negative medication effects such as nausea, stomach upset, weariness, dizziness, peripheral edema, and muscular spasms.
Long-term use has also been linked to bacterial or fungal super-infections. Despite its extensive usage, there is minimal proof that rifaximin increases serum enzyme levels or causes clinically obvious liver damage.
Segment Analysis
The global overt hepatic encephalopathy treatment market is segmented based on medications, route of administration, distribution channel and region.
Antibiotics segment accounted for approximately 39% of market share
A non-absorbable oral antibiotic is rifaximin. In addition to treating travelers' diarrhea brought on by noninvasive Escherichia coli strains, rifaximin is also used to treat overt hepatic encephalopathy in adults and manage irritable bowel syndrome associated diarrhea. Rifaximin is active against a wide range of anaerobic and aerobic gram-positive and gram-negative bacteria.
Due to its non-absorbable nature, this antibiotic is mostly used to treat infections that affect the gastrointestinal tract. Rifaximin is non-absorbable, which enables it to accumulate to high concentrations in the gastrointestinal lumen where it can treat a variety of gastrointestinal illnesses without causing systemic side effects. Bacterial transformation or drug resistance to rifaximin are extremely rare in extra-intestinal microorganisms.
On June 22, 2023, an application for a partial change to the production and distribution authorization for RIFXIMA TABLETS (rifaximin) has been submitted by ASKA Pharmaceutical Co., Ltd., a wholly owned subsidiary of ASKA Pharmaceutical Holdings Co., Ltd., for an increase in dosage and administration to pediatric patients for the treatment of hyperammonemia in hepatic encephalopathy.
Geographical Penetration
North America accounted for around 35% of market share in 2022
Due to the rising need for overt hepatic encephalopathy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for overt hepatic encephalopathy treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of medicines, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of overt hepatic encephalopathy treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global overt hepatic encephalopathy treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for overt hepatic encephalopathy treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating overt hepatic encephalopathy treatment demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global overt hepatic encephalopathy treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for overt hepatic encephalopathy treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global overt hepatic encephalopathy treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.
Key Developments
• On June 19, 2023, the XIFAXAN (rifaximin) data was provided by Bausch Health Companies Inc. and Salix Pharmaceuticals, its gastrointestinal division, and was chosen for inclusion in the Cirrhosis and its consequences session at the 2023 European Association for the Study of the Liver (EASL) Congress.
• On June 30, 2021, AXA1665, the Axcella's multi-targeted oral item candidate for lowering risk of persistent overt hepatic encephalopathy (OHE), has entered its initial clinical sites and screened patients for its worldwide Phase 2 clinical trial. Axcella is a biotechnology clinical-stage company that has invented a new approach for treating complex diseases and enhance health utilizing endogenous metabolic modulator (EMM) compositions.
Competitive Landscape
The major global players in the market include Axcella Therapeutics, COSMO PHARMACEUTICALS, Umecrine Cognition AB, Salix Pharmaceuticals (Bausch Health Companies Inc.), ASKA Pharmaceutical Holdings Co., Ltd., Lupin, Norgine, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Austria GmbH and Fengchen Group Co.,Ltd.
Why Purchase the Report?
• To visualize the global overt hepatic encephalopathy treatment market segmentation based on medications, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of overt hepatic encephalopathy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global overt hepatic encephalopathy treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Medications
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing funding and acquisitions
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the overt hepatic encephalopathy medications
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Medications
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
7.1.2. Market Attractiveness Index, By Medications
7.2. Laxatives*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Lactulose
7.2.4. Lactitol
7.3. Antibiotics
7.3.1. Rifaximin (Xifaxan)
7.4. L-ornithine L-aspartate
7.5. Probiotics or Prebiotics
7.6. Branched Chain Amino Acids
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Rectal
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Axcella Therapeutics*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. COSMO PHARMACEUTICALS
12.3. Umecrine Cognition AB
12.4. Salix Pharmaceuticals (Bausch Health Companies Inc.)
12.5. ASKA Pharmaceutical Holdings Co., Ltd.
12.6. Lupin
12.7. Norgine
12.8. Teva Pharmaceutical Industries Ltd.
12.9. Fresenius Kabi Austria GmbH
12.10. Fengchen Group Co.,Ltd
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Axcella Therapeutics, 4. Key Developments, COSMO PHARMACEUTICALS, Umecrine Cognition AB, Salix Pharmaceuticals (Bausch Health Companies Inc.), ASKA Pharmaceutical Holdings Co., Ltd., Lupin, Norgine, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Austria GmbH, Fengchen Group Co.,Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Overt Hepatic Encephalopathy Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 7 Global Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Overt Hepatic Encephalopathy Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Overt Hepatic Encephalopathy Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 14 North America Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Overt Hepatic Encephalopathy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 18 South America Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Overt Hepatic Encephalopathy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 22 Europe Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Overt Hepatic Encephalopathy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Axcella Therapeutics: Overview

Table 33 Axcella Therapeutics: Product Portfolio

Table 34 Axcella Therapeutics: Key Developments

Table 35 COSMO PHARMACEUTICALS: Overview

Table 36 COSMO PHARMACEUTICALS: Product Portfolio

Table 37 COSMO PHARMACEUTICALS: Key Developments

Table 38 Umecrine Cognition AB: Overview

Table 39 Umecrine Cognition AB: Product Portfolio

Table 40 Umecrine Cognition AB: Key Developments

Table 41 Salix Pharmaceuticals (Bausch Health Companies Inc.): Overview

Table 42 Salix Pharmaceuticals (Bausch Health Companies Inc.): Product Portfolio

Table 43 Salix Pharmaceuticals (Bausch Health Companies Inc.): Key Developments

Table 44 ASKA Pharmaceutical Holdings Co., Ltd.: Overview

Table 45 ASKA Pharmaceutical Holdings Co., Ltd.: Product Portfolio

Table 46 ASKA Pharmaceutical Holdings Co., Ltd.: Key Developments

Table 47 Lupin: Overview

Table 48 Lupin: Product Portfolio

Table 49 Lupin: Key Developments

Table 50 Norgine: Overview

Table 51 Norgine: Product Portfolio

Table 52 Norgine: Key Developments

Table 53 Teva Pharmaceutical Industries Ltd.: Overview

Table 54 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 55 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 56 Fresenius Kabi Austria GmbH: Overview

Table 57 Fresenius Kabi Austria GmbH: Product Portfolio

Table 58 Fresenius Kabi Austria GmbH: Key Developments

Table 59 Fengchen Group Co.,Ltd: Overview

Table 60 Fengchen Group Co.,Ltd: Product Portfolio

Table 61 Fengchen Group Co.,Ltd: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Overt Hepatic Encephalopathy Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 3 Global Overt Hepatic Encephalopathy Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Overt Hepatic Encephalopathy Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Overt Hepatic Encephalopathy Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Overt Hepatic Encephalopathy Treatment Market Y-o-Y Growth, By Medications, 2022-2030 (%)

Figure 7 Laxatives Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Antibiotics Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 L-ornithine L-aspartate Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Probiotics or Prebiotics Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Branched Chain Amino Acids Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Overt Hepatic Encephalopathy Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Oral Route of Administration in Global Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Rectal Route of Administration in Global Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Others Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Overt Hepatic Encephalopathy Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Overt Hepatic Encephalopathy Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 South America Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 North America Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Overt Hepatic Encephalopathy Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 28 North America Overt Hepatic Encephalopathy Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Overt Hepatic Encephalopathy Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Overt Hepatic Encephalopathy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 South America Overt Hepatic Encephalopathy Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 33 South America Overt Hepatic Encephalopathy Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Overt Hepatic Encephalopathy Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Overt Hepatic Encephalopathy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Overt Hepatic Encephalopathy Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 38 Europe Overt Hepatic Encephalopathy Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Overt Hepatic Encephalopathy Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Overt Hepatic Encephalopathy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 43 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Overt Hepatic Encephalopathy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 48 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Overt Hepatic Encephalopathy Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Axcella Therapeutics: Financials

Figure 51 COSMO PHARMACEUTICALS: Financials

Figure 52 Umecrine Cognition AB: Financials

Figure 53 Salix Pharmaceuticals (Bausch Health Companies Inc.): Financials

Figure 54 ASKA Pharmaceutical Holdings Co., Ltd.: Financials

Figure 55 Lupin: Financials

Figure 56 Norgine: Financials

Figure 57 Teva Pharmaceutical Industries Ltd.: Financials

Figure 58 Fresenius Kabi Austria GmbH: Financials

Figure 59 Fengchen Group Co.,Ltd: Financials

전 세계 간성 뇌병증 치료 시장 – 2023-2030

Global Overt Hepatic Encephalopathy Treatment Market -2023-2030